IDRA Idera Pharmaceuticals, Inc.

2.44
+0  (8%)
Previous Close 2.25
Open 2.40
Price To book 3.25
Market Cap 363.04M
Shares 149,093,000
Volume 3,743,546
Short Ratio 6.36
Av. Daily Volume 1,634,260

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 basket trial to be initiated 2H 2017.
IMO-2125
Cancer - solid tumors
Phase 1 portion of trial completed. Phase 2 arm enrolling. Overall response data due 1Q 2018.
IMO-2125
Cancer - melanoma
Development suspended - September 2016.
IMO-8400
Waldenström’s Macroglobulinemia
Development suspended - September 2016.
IMO-8400
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due 1H 2018.
IMO-8400
Dermatomyositis

Latest News

  1. The Market In 5 Minutes
  2. Today's Research Reports on Biotech Stocks to Watch: Idera Pharmaceuticals and ZIOPHARM Oncology
  3. Idera Pharmaceuticals Announces Organizational Update
  4. Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma
  5. Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting
  6. 3 Stocks the Smartest Investors are Buying Right Now
  7. ETFs with exposure to Idera Pharmaceuticals, Inc. : March 27, 2017
  8. 3 Stocks That Could Double Your Money
  9. Analyst Calls for Exponential Upside for Idera Pharmaceuticals
  10. Idera Pharmaceuticals and XOMA Find Paths to Financial Growth
  11. Idera Pharma Shares Could Be A Four-Bagger, JMP Says
  12. Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
  13. Idera posts 4Q profit
  14. Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update
  15. Idera to Present at the 37th Annual Cowen and Company Health Care Conference
  16. Idera Pharmaceuticals (IDRA) Looks Good: Stock Up 13.3%
  17. Idera Drug Combo Study Posts Positive Results
  18. Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
  19. 3 Biotech Stocks You May Be Overlooking
  20. Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development

SEC Filings

  1. 8-K - Current report 17767145
  2. CT ORDER - Confidential treatment order 17759455
  3. 10-K/A (Amend) - Annual report (Section 13 and 15(d), not S-K Item 405) 17694445
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17691934
  5. 8-K - Current report 17685838
  6. 8-K - Current report 17515824
  7. 8-K - Current report 17514326
  8. 8-K - Current report 162018630
  9. UPLOAD (Cover) - SEC-generated letter
  10. 10-Q - Quarterly report (Sections 13 or 15(d)) 161964757